PRESS RELEASE
Orion
The compound is indicated for short term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure. The final decision of the
Tasipimidine is a new active substance, a potent and selective alpha-2A adrenoceptor agonist that inhibits the release of noradrenaline from noradrenergic neurons, blocks the startle reflex and thus counteracts arousal.
Contact person:
tel. +358 10 426 4116
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to
© OMX, source